	US 12,240,886 B2
	Peptide-HLA complexes and methods of producing same
Naoto Hirano, Toronto (CA); Munehide Nakatsugawa, Sapporo (JP); Muhammed Aashiq Rahman, Brisbane (AU); and Kenji Murata, Toronto (CA)
Assigned to University Health Network, Toronto (CA)
Filed by University Health Network, Toronto (CA)
Filed on Jul. 22, 2022, as Appl. No. 17/814,401.
Application 17/814,401 is a division of application No. 16/095,913, granted, now 11,396,536, previously published as PCT/CA2017/000102, filed on Apr. 27, 2017.
Claims priority of provisional application 62/328,325, filed on Apr. 27, 2016.
Prior Publication US 2023/0192809 A1, Jun. 22, 2023
Int. Cl. A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/395 (2006.01); A61K 47/64 (2017.01); C07K 7/06 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01)

CPC C07K 14/70539 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4632 (2023.05); A61K 39/464488 (2023.05); A61K 39/464491 (2023.05); C07K 7/06 (2013.01); C12N 5/0638 (2013.01); C12N 5/0639 (2013.01); C07K 2319/02 (2013.01); C07K 2319/21 (2013.01)]

16 Claims

1. A polypeptide comprising an α1, α2 and α3 domain of an HLA class I molecule, a signal peptide at the N terminus and a 6×His tag joined by a GS linker at the C terminus, wherein:

(a) the HLA class I molecule is HLA-A and comprises the α1, α2 and α3 domain of any of SEQ ID NOs. 2, 4, 6, 8, 10, and 12;

(b) the HLA class I molecule is HLA-B and comprises the α1, α2 and α3 domain of any of SEQ ID NOs. 14, 16, 18, 20, and 22;

(c) the HLA class I molecule is HLA-C and comprises the α1, α2 and α3 domain of any of SEQ ID NOs. 24, 26, 28, and 30; or

(d) the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, or 30.